Cometriq
cabozantinib · Ipsen Pharma
ORPHAN AUTHORISED IN THE EUWhat Cometriq is used for
Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Cometriq
- Active substance
- cabozantinib
- Disease area
- Thyroid Neoplasms
- Medicine group
- Antineoplastic agents
- ATC code
- L01XE
- Marketing authorisation holder
- Ipsen Pharma
- Authorised in the EU since
- 2014
Official information
In India
- Cabozantinib: 8 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Cometriq used for?
Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma.
What is the active substance in Cometriq?
Cometriq contains cabozantinib.
Who makes Cometriq?
The EU marketing authorisation holder is Ipsen Pharma.
Is Cometriq an orphan medicine?
Yes. Cometriq is designated an orphan medicine in the EU, for a rare disease (Thyroid Neoplasms).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU